Search

Displaying results 7271 - 7280 of 7674 in total
  1. Drug

    Influenza A virus A/Texas/50/2012 X-223A (H3N2) antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB10999
    ApprovedInvestigationalWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  2. Drug

    Influenza A virus A/South Australia/55/2014 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB11001
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  3. Drug

    Influenza B virus B/Utah/9/2014 antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB11002
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  4. Drug

    Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB11038
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  5. Drug

    Influenza A virus A/Uruguay/716/2007(H3N2) hemagglutinin antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB11039
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  6. Drug

    Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB11043
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  7. Drug

    Influenza A virus A/Texas/50/2012 X-223 (H3N2) antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB11045
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  8. Drug

    Influenza A virus A/Switzerland/9715293/2013 NIB-88 (H3N2) antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB11047
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  9. Drug

    Influenza A virus A/California/7/2009(H1N1)-like hemagglutinin antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB11048
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  10. Drug

    Influenza A virus A/California/7/2009 X-179A (H1N1) hemagglutinin antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB14383
    Approved

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen